TFF PHARMACEUTICALS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-04-18: Study NCT05501574; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2021-11-14: Study NCT05168644; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2020-11-15: Study NCT04576325; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2019-11-22: Study NCT04872231; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-04-18 | NCT05501574 An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients | Lead sponsor | Phase 2 | Terminated | Lung Transplant Rejection | 14 | 2024-12-23 |
| 2021-11-14 | NCT05168644 Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects | Lead sponsor | Phase 1 | Completed | Healthy | 40 | 2022-01-26 |
| 2020-11-15 | NCT04576325 Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma | Lead sponsor | Phase 1 | Completed | Asthma | 17 | 2021-11-12 |
| 2019-11-22 | NCT04872231 Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects | Lead sponsor | Phase 1 | Completed | Healthy | 65 | 2020-08-26 |
| NCT05897294 Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis | Lead sponsor | Expanded_access | No longer available | Invasive Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis; Chronic Pulmonary Aspergillosis; Aspergillus Tracheobronchitis; Anastomotic Infection; Pulmonary Fungal Infection |